WCLC 2025 - Posters & ePosters-P3.09.01 Validation of Lung Specific-Graded Prognostic Assessment Score in NSCLC With Brain Metastases From India

P3.09.01 Validation of Lung Specific-Graded Prognostic Assessment Score in NSCLC With Brain Metastases From India

Pdf Summary

This large ambispective study from India validated the Lung Specific Graded Prognostic Assessment (Lung-GPA) score for patients with brain metastases (BM) from non-small cell lung cancer (NSCLC) treated at a tertiary cancer center. The analysis included 1197 NSCLC patients diagnosed with BM between May 2015 and May 2024. The Lung-GPA was calculated using age, Karnofsky Performance Status, number of brain metastases, and extracranial metastasis status. Overall survival (OS) was assessed from BM diagnosis until death or last follow-up using Kaplan-Meier analysis.<br /><br />The median patient age was 53 years, with 63% males. EGFR mutations were present in 37%, ALK mutations in 16%. Most patients (90%) received systemic therapy including chemotherapy (35%), tyrosine kinase inhibitors (41%), immunotherapy (2%), or combinations. The median OS for the entire cohort was 7.3 months, with a median follow-up for survivors of 42.1 months.<br /><br />Significant survival differences were seen across the Lung-GPA subgroups (p=0.001). Median OS increased with higher GPA scores: 3.5 months (GPA 0–1), 9.4 months (1.5–2), 11.7 months (2.5–3), and 14.1 months (3.5–4). This confirms Lung-GPA’s strong prognostic value in this population.<br /><br />The study is the largest Indian validation of Lung-GPA in NSCLC BM patients, demonstrating its utility in prognostication to guide personalized treatment and optimize resource use. Limitations include its largely retrospective design and smaller sample size in the highest GPA group. Overall, Lung-GPA effectively stratifies patient survival, aiding clinical decision-making in NSCLC with brain metastases in India.

Asset Subtitle

Sarath Sreekumar

Meta Tag

Speaker Sarath Sreekumar

Topic Metastatic Non-small Cell Lung Cancer – Local Therapies

Keywords

Lung Specific Graded Prognostic Assessment

Lung-GPA

non-small cell lung cancer

brain metastases

NSCLC

overall survival

EGFR mutations

ALK mutations

systemic therapy

Kaplan-Meier analysis